Abstract 1122P
Background
Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 are now the standard of care for patients with advanced melanoma, with an improvement in overall survival (OS) and quality of life. Elevated neutrophil to lymphocyte ratio (NLR) and systemic inflammatory index (SII) have been reported associated with poor survival in cancer patients, including those with ICI. The aim of this study was to determine the clinical significance of pre-treatment NLR and SII as prognostic indicator in metastatic melanoma patients treated with ICI.
Methods
Retrospective, multicentric study of metastatic melanoma patients who received ICI between 2016-2022 in two hospitals in Portugal. The SII [platelets x neutrophil/lymphocyte ratio] and NLR were calculated before the beginning of ICI. SII was considered high if > 572 and NLR was considered high if >5. Data was collected from clinical records. Statistical analysis was performed with SPSSv26. Progression free survival (PFS) and OS were assessed using Kaplan-Meier plots and log-rank testing.
Results
Eighty-nine patients were enrolled, 57 were male, mean age 68 years old. Seventy-six patients had cutaneous, 10 mucosal and 3 uveal melanoma. The type of ICI was nivolumab in 36 patients, ipilimumab/nivolumab in 34 and pembrolizumab in 19. With a median follow-up of 19 months, the median PFS and OS was 11 and 15 months, respectively. NLR was high in 12 patients. The median PFS was 3 months in NLR high vs 25 months in NLR low patients and OS was 13 months in NLR high vs 32 months. However, these differences were not statistically significant. A total of 53 patients were presented with SII high. In this group, the median PFS was 10 months vs 22 months in SII low patients (p=0.017) and the median OS was 17 months vs 32 months (p=0.032).
Conclusions
The present study suggests that elevated SII may be associated with a worse PFS and OS in metastatic melanoma patients, however, this association was not demonstrated for NLR. Thus, SII could be a prognostic value on advanced/metastatic melanoma in patients under ICI and could be an important tool in the management of these patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1160P - Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight-adjusted dose, FLATIMEL study
Presenter: Iona Campo le Brun
Session: Poster session 13
1161P - Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data
Presenter: Madona SAKKAL
Session: Poster session 13
1162P - Prolonged exposure to proton pump inhibitors (PPI) at the time of initiation of immune checkpoint blockade (ICB) mediates better clinical outcomes in patients with metastatic melanoma
Presenter: Kyrillus Shohdy
Session: Poster session 13
1163P - CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy
Presenter: Domenico Mallardo
Session: Poster session 13
1164P - Changes of TCR repertoire in metastatic melanoma and renal cell carcinoma patients treated with nivolumab correlate with overall survival
Presenter: Martin Klabusay
Session: Poster session 13
1165P - Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy
Presenter: Xinyu Bai
Session: Poster session 13
1166P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
Presenter: Giuseppe Tarantino
Session: Poster session 13
1168P - Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
Presenter: Jan-Malte Placke
Session: Poster session 13
1169P - Tumour transcriptional and spatial protein profiling in Mexican patients reveals that acral lentiginous melanoma is characterized by an immunosuppressive microenvironment
Presenter: Martha Estefania Vázquez-Cruz
Session: Poster session 13
1170P - Survival outcome prediction of primary melanoma tumours from histology images using deep learning
Presenter: Céline Bossard
Session: Poster session 13